

INNOVUS PHARMACEUTICALS, INC.

Form 8-K

September 27, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2017

INNOVUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-52991	90-0814124
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9171 Towne Centre Drive, Suite 440, San Diego, CA	92122
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (858) 964-5123

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” “the Company”, “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.

Item 8.01 – Other Events

On September 26, 2017, the Company issued a press release announcing the availability of the full label for its nasal drug FlutiCare™ (NDC: 57483-005-02) for allergy symptom relief on the U.S. Food and Drug Administration’s public drug disclosure database, DailyMed. DailyMed is the on-line database that all new drugs are described on that provides information to the public on its ingredients and usage. The DailyMed description is available through the site below:

<https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72952e6-bfe5-485b-8c62-787ff4179b62>

The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 -- Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
<u>99.1</u>	Press release issued September 27, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 27, 2017 INNOVUS PHARMACEUTICALS, INC.

By: /s/ Bassam Damaj
Bassam Damaj
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
<u>99.1</u>	Press release issued September 27, 2017.